Alembic Pharma Gets US Drug Regulator Nod For Anti-Influenza Drug
New Delhi:Drug firm Alembic Pharmaceuticals has received US health regulator's nod for Amantadine Hydrochloride capsules used to treat symptoms of infection caused by influenza virus.
"The company has received approval from the United States Food and Drug Administration (USFDA) for its ANDA for Amantadine Hydrochloride capsules USP 100 mg," Alembic Pharmaceuticals said in a BSE filing.
The approved Abbreviated New Drug Application (ANDA) is equivalent to Symmetrel capsules of Endo Pharmaceuticals.
Amantadine Hydrochloride capsules are used for the "treatment of signs and symptoms of infection caused by various strains of influenza A virus", the company said.The drug is also used in the treatment of parkinsonism and drug-induced extrapyramidal reactions, it added.
According to IMS December 2016 data, Amantadine Hydrochloride capsules had an estimated market size of $37 million.The company now has a total of 58 ANDA approvals from the USFDA.
The stock was trading at Rs 537.15, up 0.99 per cent, on the BSE.
Â
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
